当前位置: 首页 >> 检索结果
3224. WHO's adoption of SAGER guidelines and GATHER: setting standards for better science with sex and gender in mind.
作者: Shirin Heidari.;Diana Gabriela Estevez Fernandez.;Anna Coates.;Ahmad Reza Hosseinpoor.;Samira Asma.;Jeremy Farrar.;Erin Maura Kenney.
来源: Lancet. 2024年403卷10423期226-228页 3226. The future of the global clinical trial ecosystem: a vision from the first WHO Global Clinical Trials Forum.
作者: Vasee Moorthy.;Ibrahim Abubakar.;Firdausi Qadri.;Bernhards Ogutu.;Wei Zhang.;John Reeder.;Jeremy Farrar.
来源: Lancet. 2024年403卷10422期124-126页 3227. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
作者: Katherine R Tuttle.;Sibylle J Hauske.;Maria Eugenia Canziani.;Maria Luiza Caramori.;David Cherney.;Lisa Cronin.;Hiddo J L Heerspink.;Christian Hugo.;Masaomi Nangaku.;Ricardo Correa Rotter.;Arnold Silva.;Shimoli V Shah.;Zhichao Sun.;Dorothea Urbach.;Dick de Zeeuw.;Peter Rossing.; .
来源: Lancet. 2024年403卷10424期379-390页
Excess aldosterone accelerates chronic kidney disease progression. This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, and dose selection.
3230. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
作者: Chiaojung Jillian Tsai.;Jonathan T Yang.;Narek Shaverdian.;Juber Patel.;Annemarie F Shepherd.;Juliana Eng.;David Guttmann.;Randy Yeh.;Daphna Y Gelblum.;Azadeh Namakydoust.;Isabel Preeshagul.;Shanu Modi.;Andrew Seidman.;Tiffany Traina.;Pamela Drullinsky.;Jessica Flynn.;Zhigang Zhang.;Andreas Rimner.;Erin F Gillespie.;Daniel R Gomez.;Nancy Y Lee.;Michael Berger.;Mark E Robson.;Jorge S Reis-Filho.;Nadeem Riaz.;Charles M Rudin.;Simon N Powell.; .
来源: Lancet. 2024年403卷10422期171-182页
Most patients with metastatic cancer eventually develop resistance to systemic therapy, with some having limited disease progression (ie, oligoprogression). We aimed to assess whether stereotactic body radiotherapy (SBRT) targeting oligoprogressive sites could improve patient outcomes.
3232. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
作者: Inder Kaul.;Sharon Sawchak.;Christoph U Correll.;Rishi Kakar.;Alan Breier.;Haiyuan Zhu.;Andrew C Miller.;Steven M Paul.;Stephen K Brannan.
来源: Lancet. 2024年403卷10422期160-170页
New treatments with new mechanisms are urgently needed for people with schizophrenia. Xanomeline is a dual M1 and M4-preferring muscarinic receptor agonist that does not block D2 dopamine receptors, unlike all currently approved treatments for schizophrenia. Xanomeline-trospium (KarXT) combines xanomeline with the peripherally restricted muscarinic receptor antagonist trospium chloride with the goal of ameliorating xanomeline-related adverse events associated with peripheral muscarinic receptors. The EMERGENT-2 trial aimed to assess the efficacy and safety of KarXT in people with schizophrenia experiencing acute psychosis.
|